TABLE 1.
Participant Demographics
| Overall (n = 2,526) | Diagnosis During Adulthood (n = 856; 34%) | Diagnosis During Childhood (n = 1,670; 66%) | |
|---|---|---|---|
| Age, years | 35.34 (19.1, 1–90) | 48.51 (15.1, 19–90) | 28.56 (17.2, 1–84) |
| Age at diagnosis, years | 16.3 (13.3, <1–74) | 31.52 (11.5, 18–74) | 8.56 (4.5, <1–17) |
| Female sex | 1,669 (66.4) | 559 (65.8) | 1,110 (66.7) |
| White race | 2,366 (93.7) | 812 (94.9) | 1,554 (93.1) |
| Private health insurance at diagnosis | 1,929 (76.4) | 690 (80.6) | 1,239 (74.2) |
| Current insulin delivery | |||
| CSII | 1,815 (71.9) | 579 (67.6) | 1,236 (74.0) |
| MDI regimen (pen or syringe) | 872 (34.5) | 319 (37.3) | 553 (33.1) |
| Inhalable | 12 (0.5) | 8 (0.9) | 4 (0.2) |
| No insulin | 9 (0.4) | 4 (0.5) | 5 (0.3) |
| Current CGM user | 1,347 (55.5) | 476 (57.7) | 871 (54.3) |
| Most recent A1C, % | |||
| <7.0 | 929 (39.3) | 432 (53.3) | 497 (32.0) |
| ≥7.0 | 1,436 (60.7) | 379 (46.7) | 1,057 (68.0) |
Age data are expressed as mean (SD, range); all other data are expressed as n (%). CGM, continuous glucose monitoring; CSII, continuous subcutaneous insulin infusion; MDI, multiple daily injection.